新疗法改变一种易漏诊心脏病的预后：Cedars-Sinai 专家称早期诊断是关键
位于洛杉矶的 Cedars-Sinai 医疗中心发布病例报道说，转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）近年迎来多款新疗法，患者预后明显改变，早期诊断因此比以往更重要。
这种疾病源于一种名为转甲状腺素蛋白的蛋白质错误折叠，形成淀粉样纤维沉积在心脏，使心肌变硬、泵血能力下降，进而引发气短、腿部水肿，甚至心力衰竭。该病被认为较为罕见，但专家认为实际漏诊严重。
报道中的患者 Larry Teel 现年74岁，住在 Newport Beach，2024年临近退休时被确诊，一度被告知只剩两年寿命。他被转诊到 Cedars-Sinai 斯密特心脏研究所的晚期心脏病专家 Lily Stern 医生，接受非侵入性检查确诊后开始使用一款新近获批的疗法。Stern 表示，过去十年这一领域新疗法集中出现，治疗在患者出现明显心衰迹象前开始效果最好。
（来源：Cedars-Sinai 医疗中心）
New Treatments Are Changing Lives for People With Transthyretin Amyloid Cardiomyopathy, Cedars-Sinai Says
New therapies developed over the past decade are changing the outlook for people with transthyretin amyloid cardiomyopathy, a heart condition experts believe is severely underdiagnosed, Cedars-Sinai reports.
The condition occurs when a protein called transthyretin misfolds and forms amyloid fibrils that accumulate in the heart, making it stiff and unable to pump properly, causing shortness of breath, leg swelling and, as it progresses, heart failure.
One patient, Larry Teel, 74, of Newport Beach, California, was diagnosed in 2024 as he approached retirement and was told he had just two years to live. His cardiologist referred him to Dr. Lily Stern, an advanced heart disease cardiologist at the Smidt Heart Institute at Cedars-Sinai, who confirmed the diagnosis with noninvasive tests and started him on a recently approved therapy. Stern said the treatments work best when patients are diagnosed early, before significant signs of heart failure.
(Source: Cedars-Sinai)
来源：Cedars-Sinai 医疗中心
发布：GSM·美国（发布链接）
图片来源：图：Cedars-Sinai 医疗中心 Mark Goodson 大楼。Jengod 摄，CC BY-SA 4.0，经 Wikimedia Commons。 / Photo: The Mark Goodson Building at Cedars-Sinai, Los Angeles. By Jengod, CC BY-SA 4.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
